2024
Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity
Tas E, Sundararajan D, Lo J, Morelli N, Garcia-Reyes Y, Ware M, Rahat H, Ou X, Na X, Sundaram S, Severn C, Pyle L, Børsheim E, Vajravelu M, Muzumdar R, Dranoff J, Cree M. Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity. Journal Of The Endocrine Society 2024, 8: bvae110. PMID: 38895640, PMCID: PMC11185182, DOI: 10.1210/jendso/bvae110.Peer-Reviewed Original ResearchMRI fat fractionMagnetic resonance imagingPolycystic ovary syndromeVibration-controlled transient elastographyTransient elastographyDiagnostic accuracyDiagnostic accuracy of transient elastographyAccuracy of transient elastographyReceiver-operating characteristic curveFat fractionHepatosteatosis groupSignificant obesityDiagnostic performanceClinical trialsYouden indexLiver diseaseChildhood obesityHigh riskSteatotic liver diseaseLiver fatObesityResonance imagingCharacteristic curveHepatosteatosisDiagnostic methodsAASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension.
Sterling R, Asrani S, Levine D, Duarte-Rojo A, Patel K, Fiel M, Leung D, Taouli B, Alsawas M, Murad M, Dranoff J, Taddei T, Rockey D. AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension. Hepatology 2024 PMID: 38489663, DOI: 10.1097/hep.0000000000000844.Peer-Reviewed Original ResearchAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024 PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-infectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virusAASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.
Sterling R, Patel K, Duarte-Rojo A, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2024 PMID: 38489523, DOI: 10.1097/hep.0000000000000845.Peer-Reviewed Original ResearchAASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.
Sterling R, Duarte-Rojo A, Patel K, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2024 PMID: 38489518, DOI: 10.1097/hep.0000000000000843.Peer-Reviewed Original Research
2023
Coffee, adenosine, and the liver
Dranoff J. Coffee, adenosine, and the liver. Purinergic Signalling 2023, 20: 21-28. PMID: 37755557, PMCID: PMC10828332, DOI: 10.1007/s11302-023-09968-5.Peer-Reviewed Original ResearchEffects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial
Tas E, Landes R, Diaz E, Bai S, Ou X, Buchmann R, Na X, Muzumdar R, Børsheim E, Dranoff J. Effects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial. Obesity 2023, 31: 2740-2749. PMID: 37731271, PMCID: PMC11519784, DOI: 10.1002/oby.23887.Peer-Reviewed Original ResearchConceptsHigh-intensity interval trainingCardiorespiratory fitnessOral glucose tolerance testDual-energy X-ray absorptiometryAttenuation parameter (CAP) scoreIntrahepatic triglyceride contentSerum alanine aminotransferaseGlucose tolerance testSteatotic liver diseaseX-ray absorptiometryLiver magnetic resonanceCardiometabolic markersCardiometabolic healthExercise trainingHIIT protocolsLiver diseaseLiver fatExercise protocolTolerance testCRF testAlanine aminotransferaseInterval trainingMRI-PDFFTriglyceride contentObesityCoffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects
Dranoff J. Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects. AJP Gastrointestinal And Liver Physiology 2023, 324: g419-g421. PMID: 36976807, DOI: 10.1152/ajpgi.00026.2023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLiver diseaseLiver-related mortalityChronic liver diseaseFatty liver diseasePositive health outcomesPrimary active ingredientCoffee consumptionEpidemiological studiesHealth outcomesAdenosine receptorsBiological plausibilityDiseaseActive ingredientsPatientsAntagonistMortalityRecent publicationsReceptors
2022
Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes
Tas E, Bai S, Mak D, Diaz E, Dranoff J. Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes. Journal Of Diabetes And Its Complications 2022, 36: 108341. PMID: 36345110, DOI: 10.1016/j.jdiacomp.2022.108341.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseBody mass indexMajor risk factorType 1 diabetesHDL ratioHDL cholesterolLiver diseaseClinical parametersRisk factorsCAP scoresDiagnostic performanceReceiver operator curve analysisCommon liver diseaseFatty liver diseaseNon-diabetic childrenNon-obese subjectsFindings of childrenCross-sectional studyNAFLD statusClinical characteristicsGlycemic controlObese groupObese subjectsFurther workupMass indexReview of existing evidence demonstrates that methotrexate does not cause liver fibrosis
Cheema HI, Haselow D, Dranoff JA. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. Journal Of Investigative Medicine 2022, 70: 1452-1460. PMID: 36002175, DOI: 10.1136/jim-2021-002206.Peer-Reviewed Original ResearchConceptsChronic liver diseaseLiver diseaseLiver fibrosisLiver injuryPre-existing chronic liver diseaseNon-alcoholic fatty liver diseaseLong-term methotrexateMeta-analysis portionProgressive liver injurySerial liver biopsiesFatty liver diseaseAdvanced liver fibrosisCare of patientsMetabolic liver diseaseNon-invasive assessmentComprehensive literature searchAssessment of injuryMethotrexate doseAdvanced fibrosisCommon indicationDirect causeLiver biopsyTherapeutic dosesRisk factorsInclusion criteriaCOVID-19 and the liver: a narrative review of the present state of knowledge
Thandassery RB, Dranoff JA, Perisetti A, Taddei T. COVID-19 and the liver: a narrative review of the present state of knowledge. Translational Gastroenterology And Hepatology 2022, 0: 0-0. PMID: 36300154, PMCID: PMC9468988, DOI: 10.21037/tgh-20-243.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseLiver diseaseLiver injuryComorbid conditionsAcute respiratory distress syndromeDirect viral cytotoxicityNon-immunosuppressed patientsAdvanced liver diseaseLiver function testsThird of patientsEpithelial cellsRespiratory distress syndromeResolution of diseaseResolution of illnessOngoing pandemicNovel corona virus diseaseType 2 pneumocytesCOVID-19Biliary epithelial cellsGastrointestinal epithelial cellsCorona Virus DiseaseLiver dysfunctionDistress syndromeFunction testsUninterrupted careProteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways
Vazquez JH, Kennon-McGill S, Byrum SD, Mackintosh SG, Jaeschke H, Williams DK, Lee WM, Dranoff JA, McGill MR, Group A. Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways. Toxicological Sciences 2022, 187: 25-34. PMID: 35172013, PMCID: PMC9216044, DOI: 10.1093/toxsci/kfac015.Peer-Reviewed Original ResearchConceptsAcute liver failureEnd-stage liver diseaseALF patientsLactate dehydrogenaseLiver diseaseDay 1Acute Liver Failure Study GroupAcute liver failure patientsTransplant-free survivorsKing's College criteriaLiver failure patientsMost clinical laboratoriesFailure patientsLiver failurePrognostic valueControl volunteersAlanine aminotransferaseStudy groupPrognostic potentialPeak injuryDay 3Good biomarkerDay 1 samplesNonsurvivorsPatientsShort‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
McGill MR, James LP, McCullough SS, Moran JH, Mathews SE, Peterson EC, Fleming DP, Tripod ME, Vazquez JH, Kennon‐McGill S, Spencer HJ, Dranoff JA. Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. Hepatology Communications 2022, 6: 361-373. PMID: 34558847, PMCID: PMC8793989, DOI: 10.1002/hep4.1810.Peer-Reviewed Original ResearchConceptsAPAP-protein adductsAcetaminophen useCirrhosis groupClinical outcomesDay 5Sensitive biomarkerAdverse clinical outcomesShort-term administrationCompensated cirrhosisLiver injuryAPAP administrationLiver damagePK analysisCurrent guidelinesStudy initiationCirrhosisTerm safetyDay 1Day 3APAP metabolitesHigh dosesPatientsPilot studyAPAPLonger treatment
2020
Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity
Tas E, Bai S, Ou X, Mercer K, Lin H, Mansfield K, Buchmann R, Diaz EC, Oden J, Børsheim E, Adams SH, Dranoff J. Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity. Frontiers In Endocrinology 2020, 11: 654. PMID: 33071964, PMCID: PMC7533567, DOI: 10.3389/fendo.2020.00654.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseMagnetic resonance imagingIntrahepatic triglyceridesPercent changePotential biomarkersClinical weight loss programSerum fibroblast growth factorFibroblast growth factor 21Liver fat percentFatty liver diseaseWeight loss programGrowth factor 21Non-invasive biomarkersFibroblast growth factorCourse diseaseSerum FGF21Adiponectin ratioFinal visitAdiponectin levelsLiver biopsyLiver diseaseObese childrenLoss programLiver fatFactor 21The Role of Sirtuin 3 in Radiation-Induced Long-Term Persistent Liver Injury
LoBianco FV, Krager KJ, Carter GS, Alam S, Yuan Y, Lavoie EG, Dranoff JA, Aykin-Burns N. The Role of Sirtuin 3 in Radiation-Induced Long-Term Persistent Liver Injury. Antioxidants 2020, 9: 409. PMID: 32403251, PMCID: PMC7278565, DOI: 10.3390/antiox9050409.Peer-Reviewed Original ResearchLong-term liver injuryLiver injurySirtuin 3Chronic responsesRole of SIRT3Mature bile ductsPersistent liver injuryAcute liver injuryTotal body irradiationUse of radiotherapyFibrotic factorsInflammatory infiltrationBody irradiationBile ductInflammatory chemokinesMale miceGy radiationHigher DNA damageMajor mitochondrial deacetylaseAbsence of SIRT3Mitochondrial deacetylaseInjuryGlutathione peroxidaseMouse liverGy IRPurinergic Regulation of Bile Ductular Secretion
Dranoff J. Purinergic Regulation of Bile Ductular Secretion. 2020, 96-104. DOI: 10.1201/9780367813888-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsP2Y receptorsPurinergic receptorsIntestinal epitheliumExtracellular nucleotidesP2Y receptor subtypesP2 receptorsReceptor subtypesRespiratory epitheliumP1 receptorsMucin secretionNucleotide receptorsPurinergic agonistsPlatelet aggregationPurinergic regulationChloride secretionDistinct receptorsDuctular secretionNucleoside receptorsEpithelial secretionEpitheliumReceptorsSalivary glandsSecretionSecretory epitheliumRenal epithelium
2019
Reduction in SNAP-23 Alters Microfilament Organization in Myofibrobastic Hepatic Stellate Cells.
Eubanks HB, Lavoie EG, Goree J, Kamykowski JA, Gokden N, Fausther M, Dranoff JA. Reduction in SNAP-23 Alters Microfilament Organization in Myofibrobastic Hepatic Stellate Cells. Gene Expression 2019, 20: 25-37. PMID: 31757226, PMCID: PMC7284106, DOI: 10.3727/105221619x15742818049365.Peer-Reviewed Original ResearchMeSH KeywordsActin CytoskeletonActin Depolymerizing FactorsActinsAnimalsCarbon TetrachlorideCell LineCell MovementCell SeparationGene Knockdown TechniquesHepatic Stellate CellsHumansLiverLiver CirrhosisMiceMyofibroblastsQb-SNARE ProteinsQc-SNARE ProteinsRho-Associated KinasesRNA InterferenceRNA, Small InterferingSignal TransductionStress FibersWound HealingConceptsSNAP-23T-SNARE proteinsSpecific SNARE proteinsMyofibroblastic hepatic stellate cellsSNARE proteinsActin cytoskeletonActin dynamicsHepatic stellate cellsCytoskeletal reorganizationCell movementPlasma membraneHomologous proteinsExtracellular environmentMicrofilament organizationSNAP-25HSC phenotypeReceptor proteinProteinStellate cellsQuiescent hepatic stellate cellsPhenotypeCellsCritical effector cellsCytoskeletonVivo
2018
Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice
Hintermann E, Bayer M, Conti CB, Fuchs S, Fausther M, Leung PS, Aurrand-Lions M, Taubert R, Pfeilschifter JM, Friedrich-Rust M, Schuppan D, Dranoff JA, Gershwin ME, Manns MP, Imhof BA, Christen U. Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. Journal Of Autoimmunity 2018, 91: 83-96. PMID: 29753567, DOI: 10.1016/j.jaut.2018.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell AdhesionCell Adhesion MoleculesCells, CulturedCholangitis, SclerosingDisease Models, AnimalEndothelial CellsFatty Acids, MonounsaturatedFemaleFibrosisHepatitis, AutoimmuneHumansImmunoglobulinsInflammationLiverLiver Cirrhosis, BiliaryMiceMice, Inbred C57BLMice, KnockoutMyocytes, Smooth MuscleMyofibroblastsVascular RemodelingVasoconstrictionConceptsPrimary sclerosing cholangitisHepatic stellate cellsPrimary biliary cholangitisPortal fibroblastsJunctional adhesion molecule JAMEndothelial cellsLiver fibrosisBile duct stricturesChronic liver diseaseAnti-fibrosis therapyBiopsies of patientsLoss of JAMRole of JAMSmooth muscle cellsEndothelial JAMIntrahepatic vasoconstrictionFunction of JAMSclerosing cholangitisDuct stricturesLiver inflammationBiliary cholangitisBiliary fibrosisChronic modelLeukocyte infiltrationLiver disease
2017
Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
Fausther M, Lavoie E, Dranoff JA. Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*. PLOS ONE 2017, 12: e0184499. PMID: 28898276, PMCID: PMC5595315, DOI: 10.1371/journal.pone.0184499.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsLiver myofibroblastsStellate cellsFibrosis progressionLiver diseasePortal fibroblastsMesothelial cellsChronic cholestatic liver diseaseProgressive scar formationChronic liver diseaseCholestatic liver diseaseNormal mesothelial cellsSplice variantsEffector cellsOrgan failureCell surface moleculesHepatic fibrosisMyofibroblast proliferationMyofibroblast functionScar formationMesothelinPolyclonal ratCell markersMyofibroblastsCholangiocarcinoma cellsThe Cholangiocyte Adenosine‐IL-6 Axis Regulates Survival During Biliary Cirrhosis
Lavoie EG, Fausther M, Goree JR, Dranoff JA. The Cholangiocyte Adenosine‐IL-6 Axis Regulates Survival During Biliary Cirrhosis. Gene Expression 2017, 17: 327-340. PMID: 28893353, PMCID: PMC5885153, DOI: 10.3727/105221617x15042723767876.Peer-Reviewed Original ResearchConceptsBile duct ligationIL-6 releaseExogenous IL-6Common bile duct ligationBiliary cirrhosisIL-6Duct ligationInjury responseIL-6 mRNA expressionIL-6 upregulationIL-6 secretionA2B adenosine receptorsLiver cell typesA2BAR activationBile infarctsInflammatory cellsCirrhosisEpithelial responseH69 cellsIntracellular Ca2Adenosine receptorsExtracellular adenosineInduces releaseMRNA expressionRegulates Survival